FDA grants special designation for Incyte’s Jakafi treatment
June 23, 2016
The Food and Drug Administration has granted breakthrough therapy designation for ruxolitinib — Incyte Corporation’s treatment for patients with acute graft-versus-host disease. The drug, trademarked Jakafi, is the first approved […]
chat_bubble0 Comment
visibility955 Views
Premier Digital Partners
© 2024 Delaware Business Times
